APR 28, 2022 1:15 PM PDT

Lipid Supplement May Reduce Inflammation in MS

WRITTEN BY: Annie Lennon

An inflammation-mediating lipid has shown promise in reducing multiple sclerosis-related inflammation in mice. The corresponding study was published in the Journal of Neuroinflammation

Acute inflammation is a protective response to infection. After being triggered and responding to any potential threats, a series of mechanisms regulated by lipids known as specialized pro-resolving mediators (SPMs) clear it up. An error in this 'clear-up' response can lead to uncontrolled inflammation that goes on to damaged tissues. 

Multiple sclerosis (MS) is an autoimmune disorder in which the body’s immune cells attack the protective myelin sheaths around neurons and inhibit their communication ability. Inflammation is thus a crucial aspect of this condition. 

In the present study, researchers noted that both patients with MS and mouse models of MS produce insufficient levels of lipid mediators, including Maresin-1 (MaR1). They administered MaR1 to mouse models of MS to see whether it could relieve symptoms. 

The researchers found that mice who received MaR1 had reduced levels of various pro-inflammatory cytokines and immune cell counts in their spinal cord and blood. Overall, they noted that MaR1 gave clear signals of enhanced neurological outcomes and protection from demyelination. 

“This study reveals that there is an imbalance in the production of SPMs in MS patients and in [mouse models of MS], and that increasing the bioavailability of SPMs, such as MaR1, minimizes inflammation and mediates therapeutic actions,” wrote the researchers in their paper.

“Thus, these data suggest that immunoresolvent therapies, such as MaR1, could be a novel avenue for the treatment of MS,” they concluded. 

The researchers now hope to conduct a series of tests and experiments to see whether this lipid could be safely delivered to patients. If so, they may be able to take their findings to clinical trials. 

 

Sources: Science DailyJournal of Neuroinflammation

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 01, 2022
Drug Discovery & Development
Pill Form of Remdesivir Treats COVID-19 in Mice
APR 01, 2022
Pill Form of Remdesivir Treats COVID-19 in Mice
A pill form of remdesivir, an antiviral drug currently administered intravenously, may be able to treat COVID-19 in mice ...
APR 13, 2022
Immunology
Infected Immune Cells - How COVID-19 Causes Catastrophic Inflammation
APR 13, 2022
Infected Immune Cells - How COVID-19 Causes Catastrophic Inflammation
The immune system must be able to swing into action to overcome pathogenic invaders. But the inflammation that accompani ...
APR 19, 2022
Immunology
Small Genetic Differences in TB Lead to Very Different Illnesses
APR 19, 2022
Small Genetic Differences in TB Lead to Very Different Illnesses
Tuberculosis is caused by a bacterium, Mycobacterium tuberculosis, that is thought to have been around for about 150 mil ...
MAY 06, 2022
Immunology
Epstein-Barr Virus Vaccine Enters Phase 1 Trials
MAY 06, 2022
Epstein-Barr Virus Vaccine Enters Phase 1 Trials
The Epstein-Barr virus (EBV) infects most people; it's thought that when we're young, about 90 percent of us acq ...
MAY 20, 2022
Health & Medicine
What to Know About the Recent Monkeypox Outbreak
MAY 20, 2022
What to Know About the Recent Monkeypox Outbreak
First COVID, then mysterious hepatitis cases among children, now monkeypox – a rare viral illness being detected i ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
Loading Comments...